Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
Showing 1805 results
December 2023
-
Story Discovery
Innovation fueled by compassionWe're striving to help more people with chronic spontaneous urticaria—a skin condition marked by hives and distressful itching—return to their daily lives.
-
Key ReleaseNovartis investigational iptacopan Phase III study demonstrates clinically meaningful and statistically significant proteinuria reduction in patients with C3 glomerulopathy (C3G)Ad hoc announcement pursuant to Art. 53 LR Phase III APPEAR-C3G study met its primary endpoint, demonstrating superiority of iptacopan vs. placebo in proteinuria reduction at six-month analysis1;…
-
Media ReleaseNovartis presents new 48-week results from Phase III APPLY-PNH trial showing sustained efficacy and long-term safety of Fabhalta® (iptacopan) in adults with paroxysmal nocturnal hemoglobinuria (PNH)APPLY-PNH extension data show that continuous Fabhalta® (iptacopan) treatment in adults with paroxysmal nocturnal hemoglobinuria (PNH) enabled sustained hemoglobin-level increases to near-…
-
Story Patient Perspectives
Shoulder to shoulderPeople with breast cancer need better medicines that help reduce the risk and anxiety of it returning.
-
Media ReleaseLatest Novartis Kisqali® NATALEE analysis reinforces 25% reduction in risk of recurrence across broad population of patients with early breast cancer; supports regulatory submissionsWith 5.6 months of additional follow-up and 78.3% of patients having completed Kisqali® (ribociclib) investigational treatment, the updated analysis shows sustained iDFS benefit and stability in…
-
Key ReleaseNovartis receives FDA approval for Fabhalta® (iptacopan), offering superior hemoglobin improvement in the absence of transfusions as the first oral monotherapy for adults with PNHAd hoc announcement pursuant to Art. 53 LR Approval based on APPLY-PNH trial in adults with PNH and anemia despite prior anti-C5 treatment, and supported by the APPOINT-PNH study in complement…
-
Featured NewsOur next eraNovartis poised to expand impact on human health as it begins next era.
-
Story Access to Healthcare
Beacon of Hope lights the way for a more equitable futureSharing Key Insights and Lessons to Accelerate Progress.
-
Story People and Culture
How I found my true purpose at Novartis -
Story People and Culture
Belonging here: How Novartis helped me come out as a transgender woman -
Story People and Culture
Mentoring matters: how we grow together at Novartis